EMEA
European Leukodystrophies Association (ELA)
What It’s About
Leukodystrophies are a group of rare genetic diseases that destroy the central nervous system in children and adults. Symptoms vary widely with each disease but can include a loss of motor function for many. These diseases affect between 20 and 40 newborn babies in Europe each week. Thankfully, Nu Skin Europe, Middle East and Africa (EMEA) have chosen to partner with a non-profit organisation called European Leukodystrophies Association (ELA) to help raise funds for the first worldwide clinical trial of new therapeutic advancements on one leukodystrophy’s form.
How It Works
TThroughout 2020 and 2021, Nu Skin EMEA will help raise funds in the following ways:
- Nu Skin employees will participate in fundraising efforts and engage with ELA through several activities organised in the different Nu Skin EMEA offices.
- Nu Skin’s Brand Affiliates will be able to raise funds for this cause and increase awareness within their entourage. To do so, they can create a personal page by connecting to Nu Skin’s fundraising page on Alvarum, a general donation platform. Brand Affiliates and Nu Skin’s customers are also welcome to use the direct donation page.
- Product sales will also be part of Nu Skin’s efforts: €1 from every sale of the new Pharmanex Vegan Protein Shakes (available from May 2020) in the nutrition brand of Nu Skin, will be donated to this cause.
Who It Helps
ELA works to assist, and support families affected by leukodystrophies, stimulate the development of medical research and raise public awareness in Europe and further abroad.
The funds that Nu Skin EMEA collects will go towards ELA’s €500,000 contribution, which will be used to support the first worldwide clinical trial of new therapeutic advancements on one leukodystrophy’s form. The goals of this clinical trial are to increase scientific understanding and to find ways to prevent, treat, and, ultimately provide a cure.